India Strikes Back: Pharma Leaders Criticize Trump's Tariff Move

The Indian pharmaceutical sector has vocally criticized U.S. President Donald Trump's recent decision to impose a 25% tariff on Indian goods. Industry leaders argue that the tariffs could potentially harm the American healthcare system more than India's economy.

Dilip Kumar, Chairman of Medical Tourism at the Chamber of Commerce, told ANI that the Trump administration aims to damage the Indian economy but is unlikely to succeed. 'We are key exporters, especially in medical equipment and pharmaceuticals,' Kumar stated, highlighting the U.S. market's dependence on India and China for healthcare supplies.

Kumar noted the adverse effects on the U.S., predicting increased healthcare costs. Similarly, Namit Joshi, Chairman of Pharmexcil, emphasized India's crucial role in the global pharmaceutical supply chain, providing almost 47% of U.S. needs in generic drugs. He warned that tariffs could trigger shortages and prices hikes for essential drugs.

(With inputs from agencies.)